| Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem–like cells with macrophages and stromal cells H Okuda, A Kobayashi, B Xia, M Watabe, SK Pai, S Hirota, F Xing, W Liu, ... Cancer research 72 (2), 537-547, 2012 | 229 | 2012 |
| KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NFκB complex in human prostate cancer W Liu, M Iiizumi-Gairani, H Okuda, A Kobayashi, M Watabe, SK Pai, ... Journal of Biological Chemistry 286 (21), 18949-18959, 2011 | 99 | 2011 |
| Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion R Tripathi, V Modur, L Senovilla, G Kroemer, K Komurov Oncoimmunology 8 (11), 1657374, 2019 | 42 | 2019 |
| CD24 expression may play a role as a predictive indicator and a modulator of cisplatin treatment response in head and neck squamous cellular carcinoma V Modur, P Joshi, D Nie, KT Robbins, AU Khan, K Rao Plos one 11 (6), e0156651, 2016 | 32 | 2016 |
| Defective transcription elongation in a subset of cancers confers immunotherapy resistance V Modur, N Singh, V Mohanty, E Chung, B Muhammad, K Choi, X Chen, ... Nature communications 9 (1), 4410, 2018 | 19 | 2018 |
| HPV and CSC in HNSCC cisplatin resistance V Modur, KT Robbins, K Rao genome 23, 26, 2015 | 16 | 2015 |
| Characterization of immortalized human mammary epithelial cell line HMEC 2.6 PS Joshi, V Modur, JM Cheng, K Robinson, K Rao Tumor Biology 39 (10), 1010428317724283, 2017 | 12 | 2017 |
| Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity KW Kalim, JQ Yang, M Wunderlich, V Modur, P Nguyen, Y Li, T Wen, ... Journal for Immunotherapy of Cancer 10 (11), 2022 | 9 | 2022 |
| Graded RhoA GTPase expression in Treg cells distinguishes tumor immunity from autoimmunity KW Kalim, JQ Yang, V Modur, P Nguyen, Y Li, Y Zheng, F Guo Frontiers in Immunology 12, 726393, 2021 | 5 | 2021 |
| Elevated levels of CD24 in head and neck squamous carcinoma cells: A potential marker for unfavorable cisplatin response V Modur Cancer Research 75 (15_Supplement), 585-585, 2015 | 1 | 2015 |
| Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects V Modur, B Muhammad, JQ Yang, Y Zheng, K Komurov, F Guo Cell reports 42 (4), 2023 | | 2023 |
| Tumors bearing defective transcription elongation are immune hot but resistant to immune checkpoint inhibitors V Modur, F Guo The Journal of Immunology 208 (1_Supplement), 119.11-119.11, 2022 | | 2022 |
| A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers V Modur, N Singh, B Muhammad JoVE (Journal of Visualized Experiments), e59910, 2019 | | 2019 |
| Abstract B083: Defective transcription elongation in a subset of cancers confers immunotherapy resistance V Modur Cancer Immunology Research 7 (2_Supplement), B083-B083, 2019 | | 2019 |
| Abstract A50: Modeling and targeting of oncogenic proteotoxic stress in drug-resistant breast cancer N Singh, V Modur, B Muhammad, K Komurov Molecular Cancer Research 16 (8_Supplement), A50-A50, 2018 | | 2018 |
| Abstract B33: Loss of transcriptional fidelity in cancers confers immunotherapy resistance N Singh, V Modur, V Mohanty, K Choi, EM Janssen, L Privette-Vinnedge, ... Cancer Immunology Research 5 (3_Supplement), B33-B33, 2017 | | 2017 |
| The Study of CD24 as a Predictive Indicator in Cisplatin Treatment Response of Head and Neck Cancer V Modur | | 2015 |
| Use of abiraterone against a luminal androgen receptor breast cancer cell line KA Rao, V Modur, S Ghosh Cancer Research 74 (19_Supplement), 2719-2719, 2014 | | 2014 |
| Cisplatin-induced CD24 upregulation in CD44+ stem-like head and neck squamous carcinoma cells: a potential marker for unfavorable cisplatin response V Modur Cancer Research 74 (19_Supplement), 3860-3860, 2014 | | 2014 |
| Cancer stem cells and cisplatin. V Modur Cancer Research 73 (8_Supplement), 232-232, 2013 | | 2013 |
Puspa Raj Pandey, PhDMaxCyte Inc.Verified email at maxcyte.com
